320 related articles for article (PubMed ID: 36267540)
1. An Update on Novel Ocular Nanosystems with Possible Benefits in the Treatment of Corneal Neovascularization.
Zhang C; Yin Y; Zhao J; Li Y; Wang Y; Zhang Z; Niu L; Zheng Y
Int J Nanomedicine; 2022; 17():4911-4931. PubMed ID: 36267540
[TBL] [Abstract][Full Text] [Related]
2. Up-to-date molecular medicine strategies for management of ocular surface neovascularization.
Yang Y; Zhong J; Cui D; Jensen LD
Adv Drug Deliv Rev; 2023 Oct; 201():115084. PubMed ID: 37689278
[TBL] [Abstract][Full Text] [Related]
3. Gene-based antiangiogenic applications for corneal neovascularization.
Liu S; Romano V; Steger B; Kaye SB; Hamill KJ; Willoughby CE
Surv Ophthalmol; 2018; 63(2):193-213. PubMed ID: 29080632
[TBL] [Abstract][Full Text] [Related]
4. Available Therapeutic Options for Corneal Neovascularization: A Review.
Drzyzga Ł; Śpiewak D; Dorecka M; Wyględowska-Promieńska D
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791518
[TBL] [Abstract][Full Text] [Related]
5. Recent drug therapies for corneal neovascularization.
Liu X; Wang S; Wang X; Liang J; Zhang Y
Chem Biol Drug Des; 2017 Nov; 90(5):653-664. PubMed ID: 28489275
[TBL] [Abstract][Full Text] [Related]
6. Novel anti(lymph)angiogenic treatment strategies for corneal and ocular surface diseases.
Bock F; Maruyama K; Regenfuss B; Hos D; Steven P; Heindl LM; Cursiefen C
Prog Retin Eye Res; 2013 May; 34():89-124. PubMed ID: 23348581
[TBL] [Abstract][Full Text] [Related]
7. Targeting corneal inflammation by gene therapy: Emerging strategies for keratitis.
Torrecilla J; Del Pozo-Rodríguez A; Vicente-Pascual M; Solinís MÁ; Rodríguez-Gascón A
Exp Eye Res; 2018 Nov; 176():130-140. PubMed ID: 29981344
[TBL] [Abstract][Full Text] [Related]
8. Ocular neovascularization: Implication of endogenous angiogenic inhibitors and potential therapy.
Zhang SX; Ma JX
Prog Retin Eye Res; 2007 Jan; 26(1):1-37. PubMed ID: 17074526
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological Potential of Small Molecules for Treating Corneal Neovascularization.
Barry Z; Park B; Corson TW
Molecules; 2020 Jul; 25(15):. PubMed ID: 32751576
[TBL] [Abstract][Full Text] [Related]
10. In vivo effect of bevacizumab-loaded albumin nanoparticles in the treatment of corneal neovascularization.
Luis de Redín I; Boiero C; Recalde S; Agüeros M; Allemandi D; Llabot JM; García-Layana A; Irache JM
Exp Eye Res; 2019 Aug; 185():107697. PubMed ID: 31228461
[TBL] [Abstract][Full Text] [Related]
11. Corneal neovascularization: updates on pathophysiology, investigations & management.
Sharif Z; Sharif W
Rom J Ophthalmol; 2019; 63(1):15-22. PubMed ID: 31198893
[No Abstract] [Full Text] [Related]
12. Subconjunctival bevacizumab for corneal neovascularization.
Zaki AA; Farid SF
Acta Ophthalmol; 2010 Dec; 88(8):868-71. PubMed ID: 19519730
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic effects of catalpol on rat corneal neovascularization.
Han Y; Shen M; Tang LY; Tan G; Yang QC; Ye L; Ye LH; Jiang N; Gao GP; Shao Y
Mol Med Rep; 2018 Feb; 17(2):2187-2194. PubMed ID: 29207076
[TBL] [Abstract][Full Text] [Related]
14. Current and emerging therapies for corneal neovascularization.
Roshandel D; Eslani M; Baradaran-Rafii A; Cheung AY; Kurji K; Jabbehdari S; Maiz A; Jalali S; Djalilian AR; Holland EJ
Ocul Surf; 2018 Oct; 16(4):398-414. PubMed ID: 29908870
[TBL] [Abstract][Full Text] [Related]
15. Regulation of matrix metalloproteinases 2 and 9 in corneal neovascularization.
Zhang J; Wang S; He Y; Yao B; Zhang Y
Chem Biol Drug Des; 2020 May; 95(5):485-492. PubMed ID: 31002472
[TBL] [Abstract][Full Text] [Related]
16. Treatments for corneal neovascularization: a review.
Gupta D; Illingworth C
Cornea; 2011 Aug; 30(8):927-38. PubMed ID: 21389854
[TBL] [Abstract][Full Text] [Related]
17. Atorvastatin-loaded peptide amphiphiles against corneal neovascularization.
Sánchez-López E; Gómara MJ; Haro I
Nanomedicine (Lond); 2023 Jul; 18(17):1095-1108. PubMed ID: 37610088
[TBL] [Abstract][Full Text] [Related]
18. A SU6668 pure nanoparticle-based eyedrops: toward its high drug Accumulation and Long-time treatment for corneal neovascularization.
Wu H; Ye J; Zhang M; Zhang L; Lin S; Li Q; Liu Y; Han Y; Huang C; Wu Y; Cheng Y; Cai S; Ke L; Liu G; Li W; Chu C
J Nanobiotechnology; 2024 May; 22(1):290. PubMed ID: 38802884
[TBL] [Abstract][Full Text] [Related]
19. Corneal neovascularization.
Nicholas MP; Mysore N
Exp Eye Res; 2021 Jan; 202():108363. PubMed ID: 33221371
[TBL] [Abstract][Full Text] [Related]
20. Development of a naringenin microemulsion as a prospective ophthalmic delivery system for the treatment of corneal neovascularization:
Ma Y; Yang J; Zhang Y; Zheng C; Liang Z; Lu P; Song F; Wang Y; Zhang J
Drug Deliv; 2022 Dec; 29(1):111-127. PubMed ID: 34964414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
